Effect of supplementation in treatment of patients with epilepsy

Clinical trial of the effect of folate supplementation compared with the placebo on carotid intima-media thickness and metabolic profiles in patients with epilepsy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201704225623N110

Enrollment

Registered

2017-05-09

Start date

2015-03-17

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy. Episodic and paroxysmal disorders

Interventions

Intervention 1: Intervention group: Folate supplements (Tehran darou, Tehran, Iran), 5000 mg, daily, for 12 weeks orally. Intervention 2: Control group: Placebo tablet, daily for 12 weeks orally.

Eligibility

Sex/Gender

All

Age

2 Years to 12 Years

Inclusion criteria

Inclusion criteria: Aged 2 to 12 years Patients with epilepsy Receiving carbamazepine monotherapy

Exclusion criteria

Exclusion criteria: Taking folate supplements or other therapies such as vitamins or antioxidants within the last 3 months Unwillingness to cooperate Metabolic diseases Chronic medical conditions including anemia and gastrointestinal disease associated with malabsorption Neuropsychological diseases, and neurodegenerative disorders

Design outcomes

Secondary

Measure	Time frame
Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.

—

Primary

Measure	Time frame
Carotid intima-media thickness. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Sonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026